Company profile
Legend Biotech Corp
NASDAQ:LEGNBiotechnology: Pharmaceutical Preparations
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06866080 | — | withdrawn | 2025-06-17 | 2025-06-17 | Nanjing Legend Biotech Co. | A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases |
| NCT03758417 | phase2 | terminated | 2019-01-23 | 2025-07-10 | Nanjing Legend Biotech Co. | A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma |
| NCT07095075 | — | recruiting | 2025-10-14 | 2029-12-31 | Nanjing Legend Biotech Co. | A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases |
| NCT07049081 | phase1 | terminated | 2025-07-17 | 2026-03-20 | Nanjing Legend Biotech Co. | A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases |
| NCT07331272 | phase1 | recruiting | 2026-01-29 | 2028-01-31 | Nanjing Legend Biotech Co. | A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) |
FDA applications (0)
No records yet.